Topic Menu
► Topic MenuTopic Editors

Epstein-Barr Virus Disease Mechanisms and Therapeutic Strategies
Topic Information
Dear Colleagues,
Epstein–Barr virus (EBV) infects a significant percentage (>95%) of the population and establishes a persistent infection. However, most of these infections are asymptomatic. A small but significant number of EBV-positive patients develop a variety of lymphomas, including Burkitt lymphoma, diffuse large-cell B cell lymphoma, classical Hodgkin lymphoma and epithelial malignancies including nasopharyngeal carcinoma and gastric carcinoma. Furthermore, there is increasing evidence that EBV may be a trigger/driver for some autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, Sjogren’s syndrome and rheumatoid arthritis. Most studies have focused on the potential role of latency-associated gene products in these diseases, but there is accumulating evidence that the products of genes expressed during lytic or abortive-lytic activity may also be involved. This Topic is devoted to exploring the role of how molecules produced during lytic/abortive-lytic replication of EBV may contribute to modifying the host’s immune system in immunocompetent individuals and how the proteins may contribute to the disease process.
Prof. Dr. Marshall Vance Williams
Dr. Jonathan Kerr
Topic Editors
Keywords
- Epstein–Barr virus
- lytic replication
- innate immunity
- autoimmunity
- new therapeutics approaches
Participating Journals
Journal Name | Impact Factor | CiteScore | Launched Year | First Decision (median) | APC |
---|---|---|---|---|---|
![]()
Biomolecules
|
6.064 | 8.3 | 2011 | 16.6 Days | 2300 CHF |
![]()
International Journal of Molecular Sciences
|
6.208 | 7.8 | 2000 | 15.9 Days | 2500 CHF |
![]()
Pathogens
|
4.531 | 5.1 | 2012 | 15.9 Days | 2200 CHF |
![]()
Vaccines
|
4.961 | 7.0 | 2013 | 17.3 Days | 2200 CHF |
![]()
Viruses
|
5.818 | 7.1 | 2009 | 15.6 Days | 2600 CHF |